ACET - Adicet Bio, Inc. Stock Price, Fair Value and News

$0.58+0.01 (+1.75%)

Delayed as of 22 Apr 2025, 10:51 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ACET Price Action

Last 30 days

-26.0%

Last 90 days

-39.4%

Trailing 12 Months

-70.8%

ACET RSI Chart

ACET Valuation

Market Cap

47.1M

Price/Earnings (Trailing)

-0.4

Price/Sales (Trailing)

0.51

EV/EBITDA

0.08

Price/Free Cashflow

-0.5

ACET Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ACET Fundamentals

ACET Revenue

Revenue (TTM)

91.7M

ACET Earnings

Earnings (TTM)

-117.1M

Earnings Growth (Yr)

2.58%

Earnings Growth (Qtr)

5.75%

ACET Profitability

EBT Margin

-127.79%

Return on Equity

-62.76%

Return on Assets

-53.18%

Free Cashflow Yield

-198.38%

ACET Investor Care

Shares Dilution (1Y)

0.65%

Diluted EPS (TTM)

-1.33

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	50.8M	0	0	91.7M
2023	39.2M	0	0	10.0M
2022	38.7M	33.9M	73.8M	68.3M
2021	0	20.7M	16.7M	19.1M
2020	5.2M	9.4M	13.7M	17.9M
2019	0	0	0	995.0K
2018	0	0	0	8.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.

CEO	Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
WEBSITE	adicetbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	132

Adicet Bio, Inc. Frequently Asked Questions

What is the ticker symbol for Adicet Bio, Inc.? What does ACET stand for in stocks?

ACET is the stock ticker symbol of Adicet Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adicet Bio, Inc. (ACET)?

As of Mon Apr 21 2025, market cap of Adicet Bio, Inc. is 47.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACET stock?

You can check ACET's fair value in chart for subscribers.

Is Adicet Bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACET is over valued or under valued. Whether Adicet Bio, Inc. is cheap or expensive depends on the assumptions which impact Adicet Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACET.

What is Adicet Bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 21 2025, ACET's PE ratio (Price to Earnings) is -0.4 and Price to Sales (PS) ratio is 0.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACET PE ratio will change depending on the future growth rate expectations of investors.